Genome Biol:RNA印记法(RNA footprinting)用于转录组分析

2014-01-10 MedSci MedSci原创

生物学家们逐渐意识到,RNA不只是DNA和蛋白之间的过渡产物,它对调节基因的表达有重要作用。深入研究RNA调控,能够帮助科学家们进一步理解相关疾病。 宾夕法尼亚大学的科学家们开发了分析RNA调控的新方法,这一方法能够有效获得RNA与RNA结合蛋白(RBP)互作的所有位点。这一发表在Genome Biology杂志上的文章,不仅鉴定了RBP结合位点中的重要基因突变,还为其他RNA研究者提供了路线图。

生物学家们逐渐意识到,RNA不只是DNA和蛋白之间的过渡产物,它对调节基因的表达有重要作用。深入研究RNA调控,能够帮助科学家们进一步理解相关疾病。 宾夕法尼亚大学的科学家们开发了分析RNA调控的新方法,这一方法能够有效获得RNA与RNA结合蛋白(RBP)互作的所有位点。这一发表在Genome Biology杂志上的文章,不仅鉴定了RBP结合位点中的重要基因突变,还为其他RNA研究者提供了路线图。

“RNA分子生活史中的每一步都受到RBP的控制,” 文章的资深作者,助理教授Brian D. Gregory 说。“我们希望建立RBP结合位点的数据库。”这些互作发生的位点,对于理解RNA相关疾病非常重要。
“许多研究显示,RBP或RBP结合位点上的突变影响很大,特别是对大脑而言,”文章的共同第一作者Ian M Silverman说。“神经元似乎对RBP缺陷更为敏感。”
研究人员希望开发出类似于DNA印记法(DNA footprinting)的技术。此前也有一些研究团队进行了RNA印记分析,但他们是使用人工合成的核苷酸来标记蛋白互作的位点,这种方法只能在体外培养的细胞中进行,不能用于组织或整个有机体。
宾夕法尼亚大学的研究团队,在HeLa人类细胞系中对转录组进行了分析。他们通过交联将RNA分子与蛋白连接起来,然后用酶降解RNA分子,并对这些片段进行测序。RNA与蛋白结合的片段会受到保护而免于降解,而在去除了RBP的对照组中RNA不再受到这样的保护,因此对比两组的测序结果,就能揭示蛋白的结合位点。研究人员将这一方法称为PIP-seq。
这项研究验证了PIP-seq的可重复性,并且向人们展示PIP-seq得到的结果与已知的RBP结合位点相符。研究人员进一步研究RBP的结合位点发现,许多结合位点位于RNA剪切的相关区域。此外,一些反复出现的结合序列,与重要的生物学过程有关,包括发育、免疫和细胞程序性死亡。
研究人员通过数据分析指出,许多疾病相关的单核苷酸突变,发生在RBP的结合位点。例如,早发型帕金森症和迟发性皮肤卟啉病PCT中的突变,都会影响RBP与RNA的相互作用,帕金森突变干扰互作,而PCT突变增强互作。这些发现支持了近年来出现的新观点,即一些遗传学疾病(特别是神经学疾病)其实是“RNA病”。
为了帮助其他研究者分析RNA缺陷的影响,研究团队将他们的数据公布在网上。网址:http://gregorylab.bio.upenn.edu/jbrowse/?data=data/HeLa_PIPseq.

原始出处:

Silverman IM, Li F, Alexander A, Goff L, Trapnell C, Rinn JL, Gregory BD.RNase-mediated protein footprint sequencing reveals protein-binding sites throughout the human transcriptome. Genome Biol. 2014 Jan 7;15(1):R3.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1766861, encodeId=60f71e668613b, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Mar 19 08:34:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747176, encodeId=f64a1e4717629, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Aug 30 15:34:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917014, encodeId=b388191e0144e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jun 06 10:34:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654131, encodeId=9637165413171, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Fri Aug 08 16:34:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420157, encodeId=45dd142015e78, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Sun Jan 12 10:34:00 CST 2014, time=2014-01-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1766861, encodeId=60f71e668613b, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Mar 19 08:34:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747176, encodeId=f64a1e4717629, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Aug 30 15:34:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917014, encodeId=b388191e0144e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jun 06 10:34:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654131, encodeId=9637165413171, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Fri Aug 08 16:34:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420157, encodeId=45dd142015e78, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Sun Jan 12 10:34:00 CST 2014, time=2014-01-12, status=1, ipAttribution=)]
    2014-08-30 mjldent
  3. [GetPortalCommentsPageByObjectIdResponse(id=1766861, encodeId=60f71e668613b, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Mar 19 08:34:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747176, encodeId=f64a1e4717629, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Aug 30 15:34:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917014, encodeId=b388191e0144e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jun 06 10:34:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654131, encodeId=9637165413171, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Fri Aug 08 16:34:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420157, encodeId=45dd142015e78, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Sun Jan 12 10:34:00 CST 2014, time=2014-01-12, status=1, ipAttribution=)]
    2014-06-06 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1766861, encodeId=60f71e668613b, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Mar 19 08:34:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747176, encodeId=f64a1e4717629, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Aug 30 15:34:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917014, encodeId=b388191e0144e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jun 06 10:34:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654131, encodeId=9637165413171, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Fri Aug 08 16:34:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420157, encodeId=45dd142015e78, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Sun Jan 12 10:34:00 CST 2014, time=2014-01-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1766861, encodeId=60f71e668613b, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Mar 19 08:34:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747176, encodeId=f64a1e4717629, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Aug 30 15:34:00 CST 2014, time=2014-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917014, encodeId=b388191e0144e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jun 06 10:34:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654131, encodeId=9637165413171, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Fri Aug 08 16:34:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420157, encodeId=45dd142015e78, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Sun Jan 12 10:34:00 CST 2014, time=2014-01-12, status=1, ipAttribution=)]